MX2021005725A - Tratamiento de la obesidad y sus complicaciones. - Google Patents

Tratamiento de la obesidad y sus complicaciones.

Info

Publication number
MX2021005725A
MX2021005725A MX2021005725A MX2021005725A MX2021005725A MX 2021005725 A MX2021005725 A MX 2021005725A MX 2021005725 A MX2021005725 A MX 2021005725A MX 2021005725 A MX2021005725 A MX 2021005725A MX 2021005725 A MX2021005725 A MX 2021005725A
Authority
MX
Mexico
Prior art keywords
obesity
complications
treatment
seladelpar
glp
Prior art date
Application number
MX2021005725A
Other languages
English (en)
Inventor
Charles A Mcwherter
Yun- Jung Choi
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2021005725A publication Critical patent/MX2021005725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El tratamiento combinado de la obesidad y sus complicaciones con seladelpar o una sal del mismo, y un agonista de los receptores del péptido-1 similar a glucagon (GLP-1).
MX2021005725A 2018-11-16 2019-11-13 Tratamiento de la obesidad y sus complicaciones. MX2021005725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862768244P 2018-11-16 2018-11-16
PCT/US2019/061179 WO2020102351A1 (en) 2018-11-16 2019-11-13 Treatment of obesity and its complications

Publications (1)

Publication Number Publication Date
MX2021005725A true MX2021005725A (es) 2021-07-21

Family

ID=68887116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005725A MX2021005725A (es) 2018-11-16 2019-11-13 Tratamiento de la obesidad y sus complicaciones.

Country Status (5)

Country Link
US (1) US20200155487A1 (es)
EP (1) EP3880187A1 (es)
CA (1) CA3118965A1 (es)
MX (1) MX2021005725A (es)
WO (1) WO2020102351A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
CA3223121A1 (en) * 2021-06-25 2022-12-29 Eli Lilly And Company Methods for treating obstructive sleep apnea
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4928941B2 (ja) 2003-09-19 2012-05-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PT3119384T (pt) * 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
LT3129018T (lt) 2014-04-11 2020-01-10 Cymabay Therapeutics, Inc. Nafld ir nash gydymas

Also Published As

Publication number Publication date
EP3880187A1 (en) 2021-09-22
WO2020102351A1 (en) 2020-05-22
CA3118965A1 (en) 2020-05-22
US20200155487A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
MX2021005725A (es) Tratamiento de la obesidad y sus complicaciones.
AU2019378845A8 (en) Combination treatment of NAFLD and NASH
IL279300A (en) 1-GLP agonist receptors and their use
IL279224A (en) 1-GLP agonist receptors and their use
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
EP4302826A3 (en) Glucagon-like peptide 1 receptor agonists
MY197569A (en) Gip/glp1 co-agonist compounds
UA118239C2 (uk) Сполука-коагоніст gip і glp-1
EP4059929A4 (en) GLP-1 RECEPTOR AGONIST AND ITS USE
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2018010640A (es) Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX2019006600A (es) Agonistas duales de glp-1/glp-2.
MX2023002906A (es) Agonistas duales glp-1/gip.
EP4095149A4 (en) TRIPLE AGONIST FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR, GLUCAGON RECEPTOR, AND GASTRIC INHIBITOR POLYPEPTIDE RECEPTOR
MX2020007167A (es) Composiciones y metodos para tratar enfermedades metabolicas.
MX2017008715A (es) Derivados de glucagon.
MX2021005386A (es) Fragmentos de peptidos para tratamiento de diabetes.
EP3762017A4 (en) GLP-1 COMPOSITION FOR TREATMENT OF OBESITY AND WEIGHT MANAGEMENT
EP4069720A4 (en) COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY